Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02795858 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT02795858 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 43 participants.
The verdict
NCT02795858, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.
Interventions
- DRUG Ramucirumab
- DRUG Somatostatin Analog
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-06-14 |
| Est. Completion | 2023-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02795858
The ClinicalTrials.gov registry entry for NCT02795858 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ramucirumab is the first listed.
NCT02795858 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02795858 about?
NCT02795858 is a clinical study titled "A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors". This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.
What is the current status of trial NCT02795858?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2016-06-14. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT02795858?
The interventions under investigation include: Ramucirumab (DRUG), Somatostatin Analog (DRUG).
Who is sponsoring clinical trial NCT02795858?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.